Vyne Therapeutics Inc (VYNE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vyne Therapeutics Inc (VYNE) has a cash flow conversion efficiency ratio of -0.136x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.76 Million) by net assets ($27.77 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Vyne Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Vyne Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read VYNE total liabilities for a breakdown of total debt and financial obligations.
Vyne Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vyne Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Masterkool International Public Company Limited
BK:KOOL
|
-0.034x |
|
Kodi-M Co Ltd
KQ:224060
|
-0.205x |
|
Newtree S.A
BR:NEWT
|
0.060x |
|
Games Operators SA
WAR:GOP
|
0.091x |
|
EV Advanced Material Co.Ltd
KQ:131400
|
-0.068x |
|
Harte Hanks Inc
NASDAQ:HHS
|
0.189x |
|
Sidma S.A. Steel Products
AT:SIDMA
|
0.036x |
|
Personal Assets Trust plc
LSE:PNL
|
-0.015x |
Annual Cash Flow Conversion Efficiency for Vyne Therapeutics Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Vyne Therapeutics Inc from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see VYNE stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $27.77 Million | $-33.12 Million | -1.193x | -82.91% |
| 2024-12-31 | $52.09 Million | $-33.97 Million | -0.652x | -128.39% |
| 2023-12-31 | $88.73 Million | $-25.34 Million | -0.286x | +69.48% |
| 2022-12-31 | $31.20 Million | $-29.20 Million | -0.936x | +19.25% |
| 2021-12-31 | $48.64 Million | $-56.37 Million | -1.159x | +68.30% |
| 2020-12-31 | $37.49 Million | $-137.08 Million | -3.656x | -284.75% |
| 2019-12-31 | $68.51 Million | $-65.10 Million | -0.950x | -134.94% |
| 2018-12-31 | $130.38 Million | $-52.73 Million | -0.404x | -181.67% |
| 2017-12-31 | $-57.03 Million | $-28.25 Million | 0.495x | +536.45% |
| 2016-12-31 | $-29.44 Million | $-2.29 Million | 0.078x | -70.32% |
| 2015-12-31 | $-15.95 Million | $-4.18 Million | 0.262x | -- |
About Vyne Therapeutics Inc
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pa… Read more